Literature DB >> 22167776

What is the efficacy of the RTS,S malaria vaccine?

Christopher J A Duncan, Adrian V S Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22167776      PMCID： PMC3287289          DOI： 10.1136/bmj.d7728

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Malaria vaccine results face scrutiny.

Authors:  Declan Butler
Journal:  Nature       Date:  2011-10-26       Impact factor: 49.962

2.  The RTS,S malaria vaccine.

Authors:  Christopher J M Whitty
Journal:  BMJ       Date:  2011-10-27

3.  A vaccine for malaria.

Authors:  Nicholas J White
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

4.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

5.  Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.

Authors:  Marc Lievens; John J Aponte; John Williamson; Bruno Mmbando; Ali Mohamed; Philip Bejon; Amanda Leach
Journal:  Malar J       Date:  2011-08-04       Impact factor: 2.979
  5 in total
  8 in total

1.  Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans.

Authors:  Saurabh D Patel; Ambroise D Ahouidi; Amy K Bei; Tandakha N Dieye; Souleymane Mboup; Stephen C Harrison; Manoj T Duraisingh
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

Review 2.  Malaria Vaccine Development: Focusing Field Erythrocyte Invasion Studies on Phenotypic Diversity: The West African Merozoite Invasion Network (WAMIN).

Authors:  Ambroise D Ahouidi; Alfred Amambua-Ngwa; Gordon A Awandare; Amy K Bei; David J Conway; Mahamadou Diakite; Manoj T Duraisingh; Julian C Rayner; Zenon A Zenonos
Journal:  Trends Parasitol       Date:  2015-12-23

3.  Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.

Authors:  James A Gregory; Fengwu Li; Lauren M Tomosada; Chesa J Cox; Aaron B Topol; Joseph M Vinetz; Stephen Mayfield
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

4.  Analysis of Preventive Interventions for Malaria: Exploring Partial and Complete Protection and Total and Primary Intervention Effects.

Authors:  Matthew Cairns; Yin Bun Cheung; Ying Xu; Kwaku Poku Asante; Seth Owusu-Agyei; Diadier Diallo; Amadou T Konate; Alassane Dicko; Daniel Chandramohan; Brian Greenwood; Paul Milligan
Journal:  Am J Epidemiol       Date:  2015-05-27       Impact factor: 4.897

Review 5.  The case for a rational genome-based vaccine against malaria.

Authors:  Carla Proietti; Denise L Doolan
Journal:  Front Microbiol       Date:  2015-01-22       Impact factor: 5.640

6.  Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Authors:  Victorine A Mensah; Aly Gueye; Magatte Ndiaye; Nick J Edwards; Danny Wright; Nicholas A Anagnostou; Massamba Syll; Amy Ndaw; Annie Abiola; Carly Bliss; Jules-François Gomis; Ines Petersen; Caroline Ogwang; Tandakha Dieye; Nicola K Viebig; Alison M Lawrie; Rachel Roberts; Alfredo Nicosia; Babacar Faye; Oumar Gaye; Odile Leroy; Egeruan B Imoukhuede; Katie J Ewer; Philip Bejon; Adrian V S Hill; Badara Cisse
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

7.  Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.

Authors:  Ally Olotu; Gregory Fegan; Juliana Wambua; George Nyangweso; Ken O Awuondo; Amanda Leach; Marc Lievens; Didier Leboulleux; Patricia Njuguna; Norbert Peshu; Kevin Marsh; Philip Bejon
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

8.  Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.

Authors:  Freya J I Fowkes; Julie A Simpson; James G Beeson
Journal:  BMC Med       Date:  2013-10-30       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.